Advertisement

STOMPing forward: Statins, muscle complaints and CK

  • Reijo Laaksonen
    Correspondence
    Zora Biosciences Oy, Biologinkuja 1, 02150 Espoo, Finland. Tel.: +358 40 724 0771.
    Affiliations
    Zora Biosciences, Biologinkuja 1, 02150 Espoo, Finland

    Science Center, Tampere University Hospital, Tampere, Finland
    Search for articles by this author
      Reliable verification of suspected statin induced muscle side effects is a concrete clinical difficulty. This clinical challenge is further impacted by the widespread public awareness of potential adverse effects leading to increasing numbers of patients presenting with complaints [
      • Sirtori C.R.
      • Mombelli G.
      • Triolo M.
      • Laaksonen R.
      Clinical response to statins: mechanism(s) of variable activity and adverse effects.
      ]. Ballard et al. have in a previous issue of Atherosclerosis demonstrated in an extended analysis of the STOMP study [
      • Ballard K.
      • Parker B.A.
      • Capizzi J.A.
      • et al.
      Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance.
      ] that greater increases in CK levels with high-dose atorvastatin treatment did not deleteriously impact skeletal muscle function or predict skeletal muscle complaints. The strength and beauty of the STOMP study [
      • Parker B.A.
      • Capizzi J.A.
      • Grimaldi A.S.
      • et al.
      Effect of statins on skeletal muscle function.
      ] is in its careful design allowing the study of the effects of atorvastatin (80 mg) on muscle performance, exercise capacity and incidence of muscular complains in blinded, controlled and randomized fashion in statin naïve subjects.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sirtori C.R.
        • Mombelli G.
        • Triolo M.
        • Laaksonen R.
        Clinical response to statins: mechanism(s) of variable activity and adverse effects.
        Ann Med. 2011; 44: 419-432
        • Ballard K.
        • Parker B.A.
        • Capizzi J.A.
        • et al.
        Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance.
        Atherosclerosis. 2013; 230: 121-124
        • Parker B.A.
        • Capizzi J.A.
        • Grimaldi A.S.
        • et al.
        Effect of statins on skeletal muscle function.
        Circulation. 2013; 127: 96-103
        • Bruckert E.
        • Hayem G.
        • Dejager S.
        • Yau C.
        • Bégaud B.
        Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study.
        Cardiovasc Drugs Ther. 2005; 19: 403-414
        • Sullivan D.
        • Olsson A.G.
        • Scott R.
        • et al.
        Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
        JAMA. 2012; 308: 2497-2506

      Linked Article